Circular Genomics Announces Ron Rocca as Board Member
August 17, 2023
Albuquerque, New Mexico – Circular Genomics, the global leader in circular RNA biomarkers for precision psychiatry, has announced the expansion of its board of directors with the addition of Mr. Ron Rocca.
Mr. Rocca is an industry veteran with 33 years of experience attaining record profitability in highly competitive research and diagnostics markets and the commercial launch of multiple services and products. He presently serves as the CEO of Mindera Health, an AI-based skin analytics company. Previously he has served in senior leadership roles with Prometheus and Exagen Diagnostics—where his leadership took the company public.
“I am thrilled to have Ron join our Board of Directors and bring his breadth and depth of operational experience in research and diagnostics markets to Circular Genomics efforts; to deliver tests for precision psychiatry, commencing most immediately with our antidepressant therapy selection test in Q2 of 2024,” said Dr. Paul Sargeant, CEO of Circular Genomics. “Ron’s executive level leadership and vast operational expertise will be invaluable as we work with key strategic partners, launch our test to market, and secure reimbursement in the coming year.”
"The potential of circular RNA biomarkers for precision psychiatry is boundless. As a member of Circular Genomics' board, I am committed to harnessing this potential and pioneering a new era of personalized mental health solutions,” said Ron Rocca, Member of Circular Genomics Board of Directors. “I am excited to support the company towards realizing its vision of precision-driven mental health advancements.”
Ron Rocca joins the Board of Directors along with existing board members Dave Blivin (Cottonwood Technology Fund), Waneta Tuttle (Tramway Venture Partners), and Joe Cook, III (Mountain Group Partners).
ABOUT CIRCULAR GENOMICS
Circular Genomics is the leading company in the development of circular RNA-based precision medicine tools, data and diagnostics for neurology and psychiatry. The company is leveraging exclusive licenses and technologies in the use of circular RNA in major depressive disorder and other neurological diseases to disrupt and improve the standard of care. Initial products include assays to assess and direct the best treatment protocol for an individual patient and validate treatment effectiveness in days-to-weeks rather than months. For more information, please visit www.circulargenomics.com.
SOURCE Circular Genomics